20 results about "Radioresistance" patented technology

The invention belongs to the technical field of tumor treatment drug research, and particularly relates to application of a neutralizing antibody of CXCL13 in preparation of a drug for improving radiation resistance. Experiments prove that the neutralizing antibody of CXCL13 improves radiation resistance of tumor patients by reducing immunosuppressive mononuclear cells induced by radiotherapy.

In the present invention, the mRNA of the genes VTN, CXCL5, NEDD4, LCN2, SYTL4, TNFR2, and SERPING1, or the proteins encoded by these genes, exhibit differential expression levels in radioresistant lung cancer cells compared to control lung cancer cells and have a close correlation with a decrease in the survival rate of lung cancer patients. Accordingly, this preparation for measuring the expression levels of the mRNA of the genes selected from the group consisting of VTN, CXCL5, NEDD4, LCN2, SYTL4, TNFR2, and SERPING1 of the present invention or the expression levels of the proteins encoded by the genes can effectively diagnose radiation resistance in lung cancer or prognose radiation therapy for lung cancer, whereby it is possible to determine whether to perform radiation therapy and the optimal dose of radiation therapy, thus improving the efficiency and therapeutic outcomes of radiation therapy for lung cancer.

The application discloses a kind of targeted nanomedicine for treating radiation-resistant NSCLC and its preparation method and application, and belongs to the medical technical field, wherein the preparation method of targeted nanomedicine includes the following steps: using NaGdF4 as core, mesoporous silica as carrier, NaGdF4 is coated, and radio-sensitizing nanomaterial is obtained;Radio-sensitizing nanomaterial is co-incubated with PD-1 protein, and the targeted nanomedicine for treating radiation-resistant NSCLC is obtained.The application regulates radiation-resistant NSCLC tumor immune microenvironment by constructing radiosensitizing nano platform and loading PD-1 protein, controls the proliferation, migration and invasion of radiation-resistant NSCLC cells, successfully reverses the radioresistance of NSCLC, and significantly enhances the response of resistant cells to radiotherapy.The method provides valuable insights for developing targeted nanotherapeutic drugs to effectively treat NSCLC.

The invention addresses radioresistance in cancer treatment involving radiotherapy and, in particular, limitations associated with the use of the drug sulfasalazine. Specifically, it provides a series of compounds for use as radiosensitizers in the treatment of cancers such as glioblastomas which are lethal and inherently resistant to radiotherapy. In one embodiment, the invention provides compounds of general formula (I), their stereoisomers and pharmaceutically acceptable salts for use as radiosensitizers in the treatment of cancer:wherein ring A is selected from optionally substituted phenyl, biphenyl and fluorenyl; each X is independently selected from: —C1-6 alkyl (preferably C1-3 alkyl, e.g. —CH3), —O—C1-6 alkyl (preferably —O—C1-3 alkyl, e.g. —OCH3), —S—C1-6 alkyl (preferably —S—C1-3 alkyl, e.g. —SCH3), —OH, —SH, —CO2R1 (where R1 is H or C1-6 alkyl, preferably C1-3 alkyl, e.g. —CH3), —SO2—C1-6 alkyl (preferably —SO2—C1-3 alkyl, e.g. —SO2—CH3), —SO2—NR2R3 (where R2 is H and R3 is optionally substituted phenyl), —NR4R5 (wherein R4 and R5 are independently selected from H, C1-6 alkyl (preferably C1-3 alkyl, e.g. —CH3), and —CO—C1-6 alkyl (preferably —CO—C1-3 alkyl, e.g. —CO—CH3), halogen (e.g. F, Cl or Br), and optionally substituted tetrazolyl; n is an integer from 0 to 5, preferably 0 to 2, e.g. 1 or 2; and denotes an E or Z double bond.

The application provides a kind of nanoparticle for radiotherapy-copper death combined treatment breast cancer and its preparation method and application, it is suitable for the preparation field of nanoparticle, wherein the nanoparticle includes the following raw materials: 10mg precipitate A, 3~8mg CuCl2, 10mg DA.HCl, 2~6mg BSO, 100~250ul Tris-HCl buffer solution and 30~40mg BSA;The precipitate A includes the following raw materials: the mass ratio of hafnium tetrachloride and polyvinylpyrrolidone is 8:5;With can be through exogenous delivery copper ion, make intracellular copper ion accumulation, induce copper death effect, combined radiotherapy and BSO, produce strong copper death, enhance the beneficial effect of tumor cell radiation absorption and antitumor immune effect, can effectively reverse radioresistance and tumor immunosuppression microenvironment.

The invention discloses application of an SNORD3 gene family in regulating and controlling cell radiosensitivity, and belongs to the technical field of biology. In order to excavate a new tumor radiotherapy target spot, functional research is carried out on the SNORD3A / B / C / D gene, it is found that cell proliferation and clone formation can be promoted through respective overexpression of the SNORD3A / B / C / D gene, and on the contrary, cell proliferation and clone formation can be inhibited through knock-down of the SNORD3A / B / C / D gene; in addition, it is found that cell radiation resistance can be improved by inhibiting radiation-induced cell DSBs damage through respective overexpression of the SNORD3A / B / C / D genes, and otherwise, cell radiation sensitivity can be improved by knocking down the SNORD3A / B / C / D genes. The invention provides a potential target spot for tumor cell radiosensitivity intervention.

The invention discloses a human esophageal cancer radiotherapy resistance cell strain and a construction method and application thereof, the human esophageal cancer radiotherapy resistance cell strain is named as human esophageal cancer radiotherapy resistance cell strain KYSE-150-RR homo sapiens, and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: C2025261, and the preservation date is September 24, 2025. The cell strain disclosed by the invention has important application prospects in the aspects of researching an esophageal cancer radiotherapy resistance mechanism, reversing radiotherapy resistance, developing a combined treatment medicine and establishing an animal model.

The present invention relates to the pharmaceutical field, specifically to the use of bile acids and animal bile products in the preparation of tumor radiosensitizers. By examining the docking characteristics of bile acids with the EphA2 receptor binding site, their inhibitory effects on EphA2 enzyme activity, their inhibitory effects on EphA2 phosphorylation, and their radiosensitization effects on radiotherapy-resistant tumor cells, it was found that bile acids, including taurocholic acid, ursodeoxycholic acid, and tauroursodeoxycholic acid, can inhibit EphA2 enzyme activity and EphA2 phosphorylation within the nanomolar to micromolar concentration range, and can inhibit radioresistance induced by elevated EphA2 expression and / or EphA2 phosphorylation within the micromolar concentration range. Therefore, bile acids, taurocholic acid, ursodeoxycholic acid, and tauroursodeoxycholic acid have promising application as tumor radiosensitizers.

This invention discloses the application of hsa-miR-92b-5p as a biomarker for radiosensitivity in low-grade gliomas. The inventors found that high expression of hsa-miR-92b-5p indicates radioresistance in patients with low-grade gliomas, a high risk of recurrence after radiotherapy, and a poor prognosis. hsa-miR-92b-5p can serve as a biomarker for radioresistance in low-grade gliomas, enabling personalized radiotherapy for these tumors, improving treatment efficacy, and avoiding ineffective treatment.

The invention relates to the technical field of tumor treatment, and discloses a tumor mechanical environment recoding nano-carrier as well as a preparation method and application thereof. The tumor mechanical environment recoding nano-carrier designed by the invention comprises a tumor-targeted overexpressed swell-labeled ligand, manganese dioxide with response to an acidic tumor microenvironment (TME), an LDHA inhibitor for inhibiting the generation of lactic acid, and polydopamine modified gold nanoparticles. The tumor mechanical environment recoding nano-carrier which is reasonably designed can synchronously regulate metabolism (lactic acid inhibition) and immune response (cGAS-STING pathway activation), remodeling is carried out according to biomechanical characteristics (such as hardness and permeability) of a tumor mechanical microenvironment, and multi-dimensional coordinated regulation of metabolism, immunity and biomechanics is realized; the synergistic effects significantly enhance the immunotherapy effect, reverse radiation resistance and trigger systemic immune response, and have significant curative effects on primary and distant tumors.

Disclosed herein is a method for preventing or reversing CAR-T cell resistance and / or radioresistance in a relapsed and refractory diffuse large B-cell lymphoma (R / R DLBCL) of a subject, that involves assaying a sample from the subject for mRNA sequences of genes with roles in DNA damage, apoptosis, immune activation, and / or c-MYC signaling; detecting aberrant splicing in one or more of the mRNA sequences; and administering to the subject an antisense oligonucleotide (ASO) that prevents the aberrant splicing.

This invention relates to the application of DTX3 or reagents that promote DTX3 expression in the preparation of products reversing radioresistance in nasopharyngeal carcinoma (NPC), belonging to the field of biomedical technology. The invention found that, compared to parental NPC cells, Deltex E3 ubiquitin ligase 3 (DTX3) expression is significantly reduced in radioresistant NPC. Overexpression of DTX3 can reverse radioresistance in NPC cells and inhibit homologous recombination repair after radiotherapy in NPC, thus allowing DTX3 to be used to reverse radioresistance in NPC. This invention provides a new biomarker for the diagnosis of radiotherapy response in NPC, an effective method for reversing radioresistance in NPC, and a new treatment option for NPC.

The invention belongs to the field of biomedicine, and particularly relates to application of Ptpn6 knockout macrophages in breast cancer radiotherapy sensitization. Through experimental verification for the first time, Ptpn6 is determined as a key new target for regulating and controlling radiation response and functional phenotype of macrophages. The Ptpn6 gene of the macrophage is knocked out through a gene editing technology, the radiation resistance of the macrophage can be enhanced, the macrophage can continuously survive in a microenvironment after radiotherapy, the macrophage can be reprogrammed into an anti-tumor M1 sample phenotype from a tumor promoting M2 phenotype, and then the anti-tumor immunocompetence of the macrophage is enhanced. In-vitro and in-vivo experiments prove that compared with wild type macrophages, the Ptpn6 knockout macrophages can be used as a cell sensitizer to be combined with radiotherapy, so that the proliferation of tumor cells can be more effectively inhibited, the apoptosis of the tumor cells can be promoted, and the growth of in-vivo tumors can be obviously inhibited. A brand new cell treatment strategy is provided for overcoming breast cancer radiotherapy resistance.

The invention relates to the technical field of medicine preparation, in particular to application of cytokinin oTR in preparation of a medicine for enhancing tumor cell radiosensitivity. By constructing a stable tumor radiation resistance cell model and combining molecular biology experiments and statistical analysis, it is proved that cytokinin oTR can regulate and control expression of SIRT1 and miR-34a in radiation resistance cells in a time-dose dependence mode, and the radiotherapy sensitization effect is achieved through a p53 / miR-34a / SIRT1 pathway.

The invention discloses a human cervical cancer radiotherapy resistant cell strain as well as a construction method and application thereof, and belongs to the technical field of tumor radiation biology. In order to solve the technical bottlenecks of clinical disjunction, phenotype instability and single evaluation system of an existing cervical cancer cell radiation resistance model, progressive accumulative irradiation (40 times * 2Gy, the total dose is 80Gy) is performed on human cervical cancer ME180 cells, a clinical radical radiotherapy process is simulated, and a cervical cancer radiation-tolerant strain ME180-R is constructed. In the method, a maintenance irradiation strategy of 2Gy per week is innovatively introduced, so that the radiation resistance phenotype of the cell strain can be stably passed for at least 10 generations. According to the method, a quantitative evaluation system containing multi-dimensional parameters such as D0, Dq and SF2 is established at the same time. The cell strain and the construction method thereof provide reliable and stable preclinical models and tools for transformation medical research such as cervical cancer radiotherapy sensitizer screening, radiation resistance mechanism analysis, individualized radiotherapy scheme optimization and the like.

The invention discloses FOSL1 activated PRMT1 for inducing radiation resistance through DNA damage repair and invasion ways of glioblastoma, and belongs to the field of targeted gene therapy. The invention discovers that the irradiation sensitivity of glioma cells knocking down FOSL1, PRMT1 and / or CAPS is improved, and the migration and invasion are inhibited, which indicates that FOSL1, PRMT1 and / or CAPS can be used as a therapeutic target for recurrent glioma. Animal experiments verify that after the expression quantity of FOSL1, PRMT1 and / or CAPS in glioma cells in individuals is reduced, the tumor volume of glioma is effectively reduced, and the effectiveness of FOSL1, PRMT1 and / or CAPS as glioma treatment targets is proved.

In the invention, mRNA of CXCL5, CD68, MATN1, SERPING1, SNCG, VTN, FBXO4 and SYTL4 genes, or proteins coded by the genes, show different expression levels between radiation-resistant colorectal cancer cells and radiation-sensitive colorectal cancer cells, and are closely related to the reduction of the survival rate in colorectal cancer patients. Therefore, according to the present invention, an agent for measuring the expression level of mRNA of a gene selected from the group consisting of CXCL5, CD68, MATN1, SERPING1, SNCG, VTN, FBXO4, and SYTL4 or a protein encoded by the gene effectively diagnoses radiation resistance in colorectal cancer or predicts radiation therapy for colorectal cancer. This makes it possible to determine whether to perform radiation therapy and the optimal radiation dose, thereby improving the efficiency and outcome of radiation therapy for colorectal cancer.

The invention discloses a targeted nano-drug for treating radiation-resistant NSCLC and a preparation method and application thereof, and belongs to the technical field of medicines.The preparation method of the targeted nano-drug comprises the following steps that NaGdF4 serves as a core, mesoporous silica serves as a carrier, NaGdF4 is coated, and a radiosensitization nano-material is obtained; and co-incubating the radiosensitization nano-material and the PD-1 protein to obtain the targeted nano-drug for treating the radiation-resistant NSCLC. According to the invention, the radiation-sensitized nano platform is constructed and the PD-1 protein is loaded to regulate the tumor immune microenvironment of the radiation-resistant NSCLC and control the proliferation, migration and invasion of the radiation-resistant NSCLC, so that the radiation resistance of the NSCLC is successfully reversed, and the response of resistant cells to radiotherapy is remarkably enhanced. The method provides a valuable insight for developing targeted nano therapeutic drugs to effectively treat NSCLC.

The application discloses a kind of based on TRAIL high expression's biomimetic nanoenzyme composite system and preparation method and application.The application is by constructing TRAIL high expression's cell, extracts TRAIL high expression's cell membrane;The cell membrane and Cu 2‑x Se nano particle mixture, solid-liquid separation is washed after, obtains based on TRAIL high expression's Cu 2‑ x Se biomimetic nanoenzyme composite system.This system greatly improves the Cu 2‑x Se catalase and glutathione peroxidase's enzyme ability, can be better under the action of combined X ray Promote the apoptosis of radioresistant cervical cancer cell, so as to better play the role of reversing radioresistance.

This invention provides ACTA2 + MCAM + Application of cells in nasopharyngeal carcinoma patients' recurrence, radiotherapy efficacy and prognostic assessment, and treatment. This invention, based on extensive research, has discovered that ACTA2... + MCAM + Cells can serve as specific biomarkers for assessing nasopharyngeal carcinoma recurrence, radiotherapy efficacy, and prognosis; detection of ACTA2 is indicated. + MCAM + The cellular reagent can be used to prepare products for assessing nasopharyngeal carcinoma recurrence, radiotherapy efficacy, and prognosis. Furthermore, the ACTA2... + MCAM + Cells promote radioresistance in nasopharyngeal carcinoma cells by secreting type IV collagen that binds to the ITGA2 integrin receptor on the surface of the cells. This activation of the downstream PI3K-AKT signaling pathway leads to the formation of this receptor. Therefore, specific clearance of ACTA2 is crucial. + MCAM + Cells, inhibiting ACTA2 + MCAM + Cellular production of type IV collagen and blocking the binding of type IV collagen to the ITGA2 integrin receptor on the surface of tumor cells, as well as inhibiting the downstream PI3K-AKT signaling pathway, can effectively reverse the radiotherapy resistance of nasopharyngeal carcinoma and improve the efficacy of radiotherapy.